|
PTEN expression status
|
PIK3CA mutation status
|
---|
Characteristic
|
Positive
|
Negative
|
P
‡
|
Wildtype
|
Mutant
|
P
‡
|
---|
|
n = 112†
|
n = 60†
| |
n = 172†
|
n = 13†
| |
---|
Sex
| | | | | | |
Male
|
48.2 (54)
|
46.7 (28)
| |
52.0 (90)
|
23.1 (3)
| |
Female
|
51.8 (58)
|
53.3 (32)
|
0.85
|
48.0 (83)
|
76.9 (10)
|
0.04
|
Age at diagnosis (years)
|
71.0 (7.5)
|
70.0 (8.0)
|
0.43*
|
70.3 (7.7)
|
73.3 (5.6)
|
0.17*
|
Tumour location
| | | | | | |
Proximal colonic
|
34.0 (35)
|
42.9 (24)
| |
34.4 (55)
|
53.8 (7)
|
(FET)
|
Distal colonic/Rectal
|
66.0 (68)
|
57.1 (32)
|
0.27
|
65.6 (105)
|
46.2 (6)
|
0.23
|
Differentiation
| | | | | | |
Well/Moderate
|
86.9 (86)
|
87.0 (47)
| |
84.9 (129)
|
92.3 (12)
|
(FET)
|
Poor
|
13.1 (15)
|
13.0 (7.0)
|
0.98
|
15.1 (23)
|
7.7 (1)
|
0.69
|
Dukes' Stage
| | | | | | |
A/B
|
53.6 (52)
|
55.8 (29)
| |
54.4 (80)
|
61.5 (8)
| |
C/D
|
46.4 (45)
|
44.2 (23)
|
0.80
|
45.6 (67)
|
38.5 (5)
|
0.62
|
MSI status
| | | | | | |
MSS
|
83.0 (88)
|
83.3 (45)
| |
84.6 (126)
|
63.6 (7)
|
(FET)
|
MSI
|
17.0 (18)
|
16.7 (9)
|
0.96
|
15.4 (23)
|
36.4 (4)
|
0.09
|
BMI (kg/m2)
|
27.3 (4.1)
|
26.6 (4.4)
|
0.36*
|
27.3 (4.3)
|
25.7 (4.4)
|
0.20*
|
Alcohol consumption
|
9.7 (16)
|
6.6 (9.7)
|
0.17*
|
9.5 (15.0)
|
5.4 (10)
|
0.34*
|
Smoking status
| | | | | | |
Current
|
12.0 (13)
|
8.3 (5)
| |
11.2 (19)
|
0.0 (0)
| |
Former
|
46.3 (50)
|
45.0 (27)
| |
45.6 (77)
|
58.3 (7)
| |
Never
|
41.7 (45)
|
46.7 (28)
|
0.69
|
43.2 (73)
|
41.7 (5)
|
0.42
|
Physical activity
| | | | | | |
Low
|
64.3 (72)
|
70.0 (42)
| |
65.7 (113)
|
84.6 (11)
|
(FET)
|
High
|
35.7 (40)
|
30.0 (18)
|
0.45
|
34.3 (59)
|
15.4 (2)
|
0.23
|
HRT status
| | | | | | |
Current
|
10.3 (6)
|
6.5 (2)
| |
9.8 (8)
|
0.0 (0)
| |
Former
|
17.2 (10)
|
16.1 (5)
| |
17.1 (14)
|
20.0 (2)
| |
Never
|
72.4 (42)
|
77.4 (24)
|
0.81
|
73.2 (60)
|
80.0 (8)
|
0.58
|
LDL cholesterol (mmol/l)
|
4.28 (1.2)
|
3.90 (1.1)
|
0.05*
|
4.12 (1.1)
|
4.30 (1.0)
|
0.61*
|
HDL cholesterol (mmol/l)
|
1.31 (0.4)
|
1.30 (0.4)
|
0.96*
|
1.30 (0.4)
|
1.29 (0.4)
|
0.93*
|
Triglyceride (mmol/l)
|
1.99 (0.8)
|
2.25 (1.6)
|
0.17*
|
2.09 (1.1)
|
2.11 (1.5)
|
0.95*
|
Plasma vitamin C (μmol/l)
|
50.3 (18)
|
53.3 (33)
|
0.47*
|
51.2 (24)
|
54.1 (19)
|
0.71*
|
-
‡P values determined by χ2 test or Fisher's exact test when one or more expected values were less than 5 (denoted by FET). *: ANOVA tests used to calculate p-values. Results presented as % (n) or mean (±SD). HRT: hormone replacement therapy. MSI: Microsatellite instability. MSS: Microsatellite stable. † Not all individuals had data for each variable, in these cases these individuals were omitted from the test. PTEN expression data were available for 172 cases. For HRT testing only females were analysed.